

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48183 A2(51) International Patent Classification⁷: C12N 15/00 (74) Agent: BAYLISS, Geoffrey, Cyril; Boult Wade Tenant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(21) International Application Number: PCT/EP00/13149

(22) International Filing Date:
22 December 2000 (22.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9930691.2 24 December 1999 (24.12.1999) GB(71) Applicant (for all designated States except US): DEV-
GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwij-
naarde (BE).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PLAETINCK,
Geert [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE).
MORTIER, Katherine [BE/BE]; Paddenhoek 20, B-9830
St.-Martens-Latem (BE). LISSENS, Ann [BE/BE]; Tiens-
esteenweg 137, B-3010 Kessel-Lo (BE). BOGAERT,
Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk
(BE).

Published:

— Without international search report and to be republished
upon receipt of that report.For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/48183 A2

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA
INHIBITION

5 The present invention is concerned with ways of
improving the efficiency of double stranded RNA
inhibition as a method of inhibiting gene expression
in nematode worms such as *C. elegans*. In particular,
the invention relates to the finding that the
susceptibility of nematode worms such as *C. elegans* to
10 double stranded RNA inhibition is affected by changes
in the genetic background of the worms.

It has recently been described in Nature Vol 391,
pp.806-811, February 98, that introducing double
stranded RNA into a cell results in potent and
15 specific interference with expression of endogenous
genes in the cell, which interference is substantially
more effective than providing either RNA strand
individually as proposed in antisense technology. This
specific reduction of the activity
20 of the gene was also found to occur in the nematode
worm *Caenorhabditis elegans* (*C. elegans*) when the RNA
was introduced into the genome or body cavity of the
worm.

25 The present inventors have utilized the double
stranded RNA inhibition technique and applied it
further to devise novel and inventive methods of (i)
assigning functions to genes or DNA fragments which
have been sequenced in various projects, such as, for
example, the human genome project and which have yet
30 to be accorded a particular function, and (ii)
identifying DNA responsible for conferring a
particular phenotype. Such methods are described in
the applicant's co-pending application number WO
00/01846. Processes for introducing RNA into a living
35 cell, either *in vivo* or *ex vivo*, in order to inhibit
expression of a target gene in that cell are

additionally described in WO 99/32619.

Several different experimental approaches can be used to introduce double-stranded RNA into nematode worms in order to achieve RNA interference *in vivo*.

5 One of the most straightforward approaches is simple injection of double-stranded RNA into a body cavity. A more elegant solution is to feed the nematodes on food organisms, generally bacteria, which express a double stranded RNA of the appropriate sequence, 10 corresponding to a region of the target gene.

The present inventors have now determined that the phenomenon of RNA interference in nematodes following ingestion of food organisms capable of expressing double-stranded RNA is dependent both on 15 the nature of the food organism and on the genetic background of the nematodes themselves. These findings may be exploited to provided improved methods of double-stranded RNA inhibition.

Therefore, according to a first aspect of the 20 present invention there is provided a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence 25 substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.

30 *Caenorhabditis elegans* is the preferred nematode worm for use in the method of the invention although the method could be carried out with other nematodes and in particular with other microscopic nematodes, 35 preferably microscopic nematodes belonging to the genus *Caenorhabditis*. As used herein the term "microscopic" nematode encompasses nematodes of

approximately the same size as *C. elegans*, being of the order 1mm long in the adult stage. Microscopic nematodes of this approximate size can easily be grown in the wells of a multi-well plate of the type 5 generally used in the art to perform mid- to high-throughput screening.

It is an essential feature of this aspect of the invention that the nematode has a non wild-type 10 genetic background which confers greater sensitivity to RNA interference phenomena (abbreviated herein to RNAi) as compared to the equivalent wild type nematodes. As illustrated in the accompanying 15 examples, introduction of double-stranded RNA (abbreviated herein to dsRNA) into a non wild-type strain according to the invention results in greater inhibition of expression of the target gene. Depending on the nature of the target gene, this greater level of inhibition may be detectable at the phenotypic level as a more pronounced phenotype.

20 The nematode having non wild-type genetic background may, advantageously, be a mutant strain. Mutations which have the effect of increasing 25 susceptibility of the nematode to RNAi may, for example, affect the stability of dsRNA or the kinetics of dsRNA turnover within cells of the worm or the rate of uptake of dsRNA synthesised by a food organism. Suitable mutant strains include mutant strains 30 exhibiting knock-out or loss-of-function mutations in one or more genes encoding proteins involved in RNA synthesis, RNA degradation or the regulation of these processes.

In one preferred embodiment, the nematode is a 35 mutant strain, more preferably a mutant *C. elegans*, which exhibits reduced activity of one or more nucleases compared to wild-type. Suitable strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding

nucleases, such as RNases. A particularly preferred example is the *nuc-1* strain. This mutant *C. elegans* strain is known *per se* in the art.

In a second preferred embodiment, the nematode is 5 a mutant strain, more preferably a mutant *C. elegans*, which exhibits increased gut uptake compared to wild-type. Particularly preferred examples of such strains are the so-called *C. elegans* gun mutants described herein. In a still further embodiment, the nematode 10 may be a transgenic worm comprising one or more transgenes which increase gut uptake relative to wild-type.

The term "increased gut uptake" as used herein is 15 taken to mean increased uptake of foreign particles from the gut lumen and may encompass both increased gut permeability and increased gut molecular transport compared to wild-type *C. elegans*.

C. elegans feeds by taking in liquid containing 20 its food (e.g. bacteria). It then spits out the liquid, crushes the food particles and internalises them into the gut lumen. This process is performed by the muscles of the pharynx. The process of taking up liquid and subsequently spitting it out is called 25 pharyngeal pumping. Once the food particles have been internalised via pharyngeal pumping their contents must cross the gut itself in order to reach target sites in the worm. There are multiple factors which 30 effect the uptake of compounds from the gut lumen to the surrounding tissues. These include the action of multi-drug resistance proteins, multi-drug resistance related proteins and the P450 cytochromes as well as other enzymes and mechanisms available for transport of molecules through the gut wall.

C. elegans mutants which exhibit increased uptake 35 of foreign molecules through the gut may be obtained from the *C. elegans* mutant collection at the C.

elegans Genetic Center, University of Minnesota, St Paul, Minnesota, or may be generated by standard methods. Such methods are described by Anderson in Methods in Cell Biology, Vol 48, "C. elegans: Modern 5 biological analysis of an organism" Pages 31 to 58. Several selection rounds of the PCR technique can be performed to select a mutant worm with a deletion in a desired gene. Alternatively, a population of worms could be subjected to random mutagenesis and worms 10 exhibiting the desired characteristic of increased gut uptake selected using a phenotypic screen, such as the dye uptake method described herein.

As an alternative to mutation, transgenic worms 15 may be generated with the appropriate characteristics. Methods of preparing transgenic worms are well known in the art and are particularly described by Craig Mello and Andrew Fire, Methods in Cell Biology, Vol 48, Ed. H.F. Epstein and D.C. Shakes, Academic Press, pages 452-480.

20 Worms exhibiting the desired characteristics of increased gut uptake can be identified using a test devised by the inventors based on uptake of a marker precursor molecule which is cleaved by the action of enzymes present in the gut lumen to generate a marker 25 molecule which produces a detectable signal, such as fluorescence. A suitable marker precursor molecule is the fluorescent dye precursor BCECF-AM available from Molecular Probes (Europe BV), Netherlands. This dye only becomes fluorescent when cleaved by esterases and 30 maintained at a pH above 6. The pH of the gut lumen is usually 5 or below. Thus, any BCECF-AM taken up through the pharynx into the gut lumen is not fluorescent until cleaved and the cleaved portion has entered the cells surrounding the lumen which are at a 35 higher pH. Thus, this dye is able to quickly identify mutant or otherwise modified worms which have increased gut transport or permeability. There is a

gradual increase in fluorescence in the tissues surrounding the gut while the gut lumen remains dark. The fluorescence can be detected at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

5 Specific examples of gun mutant strains isolated using this procedure which may be used in the method of the invention are strains bg77, bg84, bg85 and bg86, although it is to be understood that the 10 invention is in no way limited to the use of these specific strains. The *C. elegans* gun mutant strain bg85 was deposited on 23 December 1999 at the BCCM/LMG culture collection, Laboratorium Voor Microbiologie, Universiteit Gent, K. L. Ledeganckstraat 35, B-9000, 15 Gent, Belgium under accession number LMBP 5334CB. The phrase "the bg85 mutation" as used herein refers to the specific mutation(s) present in the bg85 strain which is/are responsible for conferring the gun phenotype.

20 It is also within the scope of the invention to use a non wild-type nematode strain, preferable a *C. elegans* strain, having multiple mutations which affect sensitivity to RNAi. A preferred type of multiple mutant is one having at least one mutation which 25 results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type. An example of such a mutant is a *C. elegans* strain having the *nuc-1* mutation and at least one further gun 30 mutation. As exemplified herein, double mutants having the *nuc-1* mutation and a gun mutation exhibit enhanced sensitivity to RNAi as compared to either *nuc-1* or gun single mutants.

35 For the avoidance of doubt, where particular characteristics or properties of nematode worms are described herein by relative terms such as "enhanced"

or "increased" or "decreased" this should be taken to mean enhanced, increased or decreased relative to wild-type nematodes. In the case of *C. elegans*, wild-type is defined as the N2 Bristol strain which is well known to workers in the *C. elegans* field and has been extremely well characterised (see Methods in Cell Biology, Volume 48, *Caenorhabditis elegans: Modern biological analysis of an organism*, ed. by Henry F. Epstein and Diane C. Shakes, 1995 Academic Press; The nematode *Caenorhabditis elegans*, ed. by William Wood and the community of *C. elegans* researchers., 1988, Cold Spring Harbor Laboratory Press; *C. elegans II*, ed. by Donald L. Riddle, Thomas Blumenthal, Barbara J. Meyer and James R. Priess, 1997, Cold Spring Harbor Laboratory Press). The N2 strain can be obtained from the *C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, USA.

The food organism for use in the above aspect of the invention is preferably a bacterium such as, for example, a strain of *E.coli*. It will, however, be appreciated that any other type of food organism on which nematodes feed and which is capable of producing dsRNA could be used. The food organism may be genetically modified to express a double-stranded RNA of the appropriate sequence, as will be understood with reference to the examples included herein. One convenient way in which this may be achieved in a bacterial food organism is by transforming the bacterium with a vector comprising a promoter or promoters positioned to drive transcription of a DNA sequence to RNA capable of forming a double-stranded structure. Examples of such vectors will be further described below.

The actual step of feeding the food organism to the nematode may be carried out according to procedures known in the art, see WO 00/01846.

Typically the feeding of the food organisms to the nematodes is performed on standard agar plates commonly used for culturing *C. elegans* in the laboratory. However, the step of feeding the food 5 organism to the nematodes may also be carried out in liquid culture, for example in the wells of 96-well microtitre assay plates.

The inventors have further observed that variations in the food organism can result in enhanced 10 *in vivo* RNAi when the food organism is ingested by a nematode worm.

Accordingly, in a further aspect the invention provides a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said 15 nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a 20 modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

The modification present in the food organism can be any modification which results in increased 25 expression of the dsRNA or in increased persistence of the dsRNA. Suitable modifications might include mutations within the bacterial chromosome which affect RNA stability and/or degradation or mutations which have a direct effect on the rate of transcription. In 30 a preferred embodiment, the food organism is an RNase III minus *E. coli* strain, or any other RNase negative strain.

According to a still further aspect of the invention there is provided a method of inhibiting 35 expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide

sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

5 In addition to exhibiting increased sensitivity to RNAi following feeding with food organisms capable of expressing a dsRNA, nematodes which exhibit increase gut uptake as described herein also show increased uptake of DNA molecules capable of producing
10 double-stranded RNA structures following ingestion into a nematode.

In a preferred embodiment, the DNA is in the form of a vector comprising a promoter or promoters orientated to relative to a sequence of DNA such that
15 they are capable of driving transcription of the said DNA to make RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to the promoter or promoters.

Several different arrangements of promoters may
20 be used in such a vector. In a first arrangement a DNA fragment corresponding to a region of the target gene is flanked by two opposable polymerase-specific promoters which are preferably identical.

Transcription from the opposable promoters produces
25 two complementary RNA strands which can anneal to form an RNA duplex. The plasmid pGN1 described herein is an example of a vector comprising two opposable T7 promoters flanking a multiple cloning site for insertion of a DNA fragment of the appropriate sequence, corresponding to a region of a target gene.
30 pGN8 is an example of a vector derived from pGN1 containing a fragment of the *C. elegans unc-22* gene. In an alternative arrangement, DNA fragments corresponding to a region of the target gene may be
35 placed both in the sense and the antisense orientation downstream of a single promoter. In this case, the sense/antisense fragments are co-transcribed to

generate a single RNA strand which is self-complementary and can therefore form an RNA duplex.

In both of the above arrangements, the polymerase-specific T3, T7 and SP6 promoters, all of which are well known in the art, are useful for driving transcription of the RNA. Expression from these promoters is dependent on expression of the cognate polymerase. Advantageously, the nematode itself may be adapted to express the appropriate polymerase. Expression of the polymerase may be general and constitutive, but could also be regulated under a tissue-specific promoter, an inducible promoter, a temporally regulated promoter or a promoter having a combination of such characteristics.

Transgenic *C. elegans* strains harboring a transgene encoding the desired polymerase under the control of an appropriately-regulated promoter can be constructed according to methods known *per se* in the art and described, for example, by Craig Mello and Andrew Fire in Methods in Cell Biology, Vol 48, Ed. H. F. Epstein and D. C. Shakes, Academic Press, pp 452-480.

The advantage of adapting the nematode to express the required polymerase is that it is possible to control inhibition of expression of the target gene in a tissue-specific and/or temporally specific manner by placing expression of the polymerase under the control of an appropriately regulated promoter.

Introduction of DNA into nematodes in accordance with the method of the invention can be achieved using a variety of techniques, for example by direct injection into a body cavity or by soaking the worms in a solution containing the DNA. If the DNA is in the form of a vector as described herein, e.g. a plasmid harboring a cloned DNA fragment between two flanking T7 promoters, then dsRNA corresponding to this DNA fragment will be formed in the nematode resulting in down regulation of the corresponding gene. The

introduced DNA can form an extrachromosomal array, which array might result in a more catalytic knock-out or reduction of function phenotype. The DNA might also become integrated into the genome of the nematode, 5 resulting in the same catalytic knock out or reduction of function phenotype, but which is stably transmittable.

In each aspect of the invention, the double-stranded RNA structure may be formed by two separate 10 complementary RNA strands or a single self-complementary strand, as described above. Inhibition of target gene expression is sequence-specific in that only nucleotide sequences corresponding to the duplex region of the dsRNA structure are targeted for 15 inhibition.

It is preferred to use dsRNA comprising a nucleotide sequence identical to a portion of the target gene, although RNA sequences with minor variations such as insertions, deletions and single 20 base substitutions may also be used and are effective for inhibition. It will be readily apparent that 100% sequence identity between the dsRNA and a portion of the target gene is not absolutely required for inhibition and the phrase "substantially identical" as 25 used herein is to be interpreted accordingly. Generally sequences which are substantially identical will share at least 90%, preferably at least 95% and more preferably at least 98% nucleic acid sequence 30 identity. Sequence identity may be conveniently calculated based on an optimal alignment, for example using the BLAST program accessible at WWW.ncbi.nlm.nih.gov.

The invention will be further understood with reference to the following non-limiting Examples, 35 together with the accompanying Figures in which:

Figure 1 is a plasmid map of the vector pGN1

containing opposable T7 promoters flanking a multiple cloning site and an ampicillin resistance marker.

5 Figure 2 is a plasmid map of the vector pGN8 (a genomic fragment of the *C. elegans* unc-22 gene cloned in pGN1).

10 Figure 3 is a plasmid map of the vector pGN29 containing two T7 promoters and two T7 terminators flanking *Bst*XI sites. This vector permits cloning of DNA fragments linked to *Bst*XI adaptors.

15 Figure 4 is a plasmid map of the vector pGN39 containing two T7 promoters and two T7 terminators flanking attR recombination sites (based on the Gateway™ cloning system of Life Technologies, Inc).

20 Figure 5 is a plasmid map of the vector pGX22 (a fragment of the *C. elegans* gene C04H5.6 cloned in pGN29).

Figure 6 is a plasmid map of the vector pGX52 (a fragment of the *C. elegans* gene K11D9.2b cloned in pGN29).

25 Figure 7 is a plasmid map of the vector pGX104 (a fragment of the *C. elegans* gene Y57G11C.15 cloned in pGN29).

30 Figure 8 is a plasmid map of the vector pGZ8 (a fragment of the *C. elegans* gene T25G3.2 cloned in pGN39).

35 Figure 9 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the

plasmid pGX22.

Figure 10 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 5 liquid culture were fed with *E. coli* containing the plasmid pGX52.

Figure 11 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 10 liquid culture were fed with *E. coli* containing the plasmid pGXGZ8.

Figure 12 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 15 liquid culture were fed with *E. coli* containing the plasmid pGX104

Example 1

Influence of genetic background on the efficiency of RNAi in *C. elegans*.

5 **Introduction**

Various different *C. elegans* strains were fed with different bacteria, to test the possibility of RNAi by feeding *C. elegans* with bacteria that produce dsRNA. The possibility of DNA delivery and dsRNA delivery has 10 previously been envisaged by using different bacterial strains. In this experiment the importance of the *C. elegans* strain as receptor of the dsRNA is also shown.

For this experiment the following *E. coli* strains were 15 used:

1. MC1061: F-araD139 Δ (ara-leu)7696 galE15 galK16 Δ (lac)X74 rpsL (Str^r) hsdR2 ($r_k^- m_k^+$) mcrA mcrB1
 - regular host for various plasmids,
 - Wertman et al., (1986) Gene 49:253-262,
 - Raleigh et al., (1989) in Current Protocols in Molecular Biology eds. Ausubel et al, Publishing associates and Wiley Interscience; New York. Unit 1.4.
2. B21(DE3): F- *ompT*(lon) hsdS_B ($r_B^- m_B^-$); an *E. coli* B strain) with DE3, a λ prophage carrying the T7 RNA polymerase gene.
 - regular host for IPTG inducible T7 polymerase expression,
 - Studier et al. (1990) Meth. Enzymol. 185:60-89
3. HT115 (DE3): F- mcrA mcrB IN(rrnD-rrnE) 1 λ -*rnc14::tr10* (DE3 lysogen: lacUV5 promoter-T7polymerase)
 - host for IPTG inducible T7 polymerase

expression,
- RNaseIII-,
- Fire A, Carnegie Institution, Baltimore, MD,
Pers. Comm.

5

For this experiment the following *C. elegans* strains were used:

1. *C. elegans* N2: regular WT laboratory strain
- 10 2. *C. elegans* *nuc-1*(e1393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death; ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described:
15 e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)
- Stanfield et al. (1998) East Coast Worm meeting abstract 171,
20 - Anonymous, Worm Breeder's Gazette 1(1):17b
Hevelone et al. (1988) Biochem. Genet. 26:447-461
- Ellis et al., Worm breeder's Gazette 7(2):44
- Babu, Worm Breeder's gazette 1(2):10
25 - Driscoll, (1996) Brain Pathol. 6:411-425
- Ellis et al., (1991) Genetics 129:79-94

For this experiment the following plasmids were used:

30 pGN1: A vector encoding for ampicillin resistance, harbouring a multiple cloning site between two convergent T7 promoters.

35 pGN8: pGN1 containing a genomic fragment of *unc-22*. Decreased *unc-22* expression via RNAi results in a "twitching" phenotype in *C. elegans*.

Experimental conditions

12-well micro-titer plates were filled with approximately 2 ml of NGM agar per well (1 litre of NGM agar: 15g Agar, 1g peptone, 3g NaCl, 1ml 5 cholesterol solution (5 mg/ml in EtOH), with sterile addition after autoclaving of 9.5 ml 0.1M CaCl₂, 9.5 ml 0.1 ml MgSO₄, 25 ml 1M KH₂PO₄/K₂HPO₄ buffer pH 6 and 5 ml nystatin solution (dissolved 10 mg/ml in 1:1 EtOH:CH₃COONH₄ 7.5 M).

10 The dried plates were spotted with approximately 50 µl of an overnight culture of bacteria. When IPTG induction was required, 50 µl of a 10 mM stock solution of IPTG was dropped on top of the bacteria 15 lawn, and incubated at 37°C for approximately 4 hours. Individual nematodes at the L4 growth stage were then placed in single wells. In each well 4 nematodes, and the plates were further incubated at 20°C for 6 days to allow offspring to be formed. The F1 offspring of 20 the seeded nematodes were tested for the twitching phenotype.

Results

Table 1: Percentage of the offspring that show the twitching phenotype

	MC1061	N2	<i>nuc-1</i>
5	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	0%	0%
	pGN8 + IPTG	0%	0%
10	BL21 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	20% (+)	>90% (++)
	pGN8 + IPTG	20% (+)	>90% (++±)
15	HT115 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	50% (+±)	>90% (++)
	pGN8 + IPTG	80% (++)	>90% (+++)

20

%: percentage twitchers

+: weak twitching

++: twitching

+++: strong twitching

25

Conclusions

The experiment with *E. coli* MC1061 shows that no twitching could be observed in this experiment.

30 Neither the N2 nematodes nor the *nuc-1* nematodes showed any twitchers. This is to be expected as *E. coli* MC1061 does not produce any T7 RNA polymerase, and hence the unc-22 fragment cloned in pGN8 is not

expressed as dsRNA.

The experiment with *E. coli* strain BL21(DE3) and nematode strain N2 shows expected results. BL21(DE3) harbouring plasmid pGN1 does not result in any twitching as the pGN1 vector is an empty vector. BL21 (DE3) harbouring PGN8 results in the expression of unc-22 dsRNA. When this dsRNA is fed to the N2 nematode (indirectly by feeding with the bacteria that produce the dsRNA), this results in a twitching phenotype, indicating that the dsRNA is able to pass the gut barrier and is able to perform its interfering activity.

Surprisingly the RNAi effect of the unc-22 dsRNA was even more pronounced in *C. elegans* strain *nuc-1* than in the wild type N2 strain. Although one may expect that the *nuc-1* mutation results in the non-degradation or at least in a slower degradation of DNA, as the NUC-1 protein is known to be involved in DNase activity, we clearly observe an enhancement of the RNAi induced phenotype in *C. elegans* with a *nuc-1* background. The *nuc-1* mutation has not been cloned yet, but it has been described that the gene is involved in nuclease activity, and more particularly DNase activity. If the NUC-1 protein is a nuclease, it may also have activity on nuclease activity on dsRNA, which would explain the enhanced RNAi phenotype. The *nuc-1* gene product may be a nuclease, or a regulator of nuclease activity. As the mode of action of RNAi is still not understood, it is also possible that the NUC-1 protein is interfering in the mode of action of RNAi. This would explain why a *nuc-1* mutant is more sensitive to RNAi.

35

The experiment with the *E. coli* strain HT115 (DE3)

confirms the experiments with the BL21(DE3) strain. The RNA interference observed with the unc-22 dsRNA is even higher. In comparison with strain BL21(DE3) this could be expected, as HT115(DE3) is a RNase III minus 5 strain, and hence is expected to produce larger amounts of dsRNA, resulting in more prominent RNAi. This indicates further that the RNAi observed in this experiment is the result of the dsRNA produced by the bacteria fed to the *C. elegans*. Feeding *C. elegans* 10 *nuc-1* with HT115(DE3) harbouring pGN8 also results in higher RNA interference phenotype than feeding the same bacteria to *C. elegans* wild-type strain N2. Once again this indicates that improved RNAi can be realised using a nuclease negative *C. elegans* and more 15 particularly with a with the *C. elegans* *nuc-1* (e1392) strain.

Summary

RNA interference can be achieved in *C. elegans* by 20 feeding the worms with bacteria that produce dsRNA. The efficiency of this RNA interference is dependent both on the *E. coli* strain and on the genetic background of the *C. elegans* strain. The higher the level of dsRNA production in the *E. coli*, the more 25 RNAi is observed. This can be realised by using efficient RNA expression systems such as T7 RNA polymerase and RNAase negative strains, such as RNaseIII minus stains. In this example the level of dsRNA production varied: HT115(DE3)>BL21(DE3)>MC1061.

30 RNA interference is high in *C. elegans* strains that are nuclease negative, or that are influenced in their nuclease activity. This can be realised by using a mutant strain such as *C. elegans* *nuc-1*. 35 In this example the sensitivity to RNAi varied: *C. elegans* *nuc-1* >> *C. elegans* N2

Example 2

Improved RNAi by feeding dsRNA producing bacteria in selected *C. elegans* strains-Comparison of the *nuc-1* strain with several mutants which show improved gut uptake. (designated herein 'gun' mutants). Strains 5 *bg77*, *bg78*, *bg83*, *bg84*, *bg85*, *bg86*, *bg87*, *bg88* and *bg89* are typical gun mutant *C. elegans* strains isolated using selection for increased gut uptake (gun phenotype) with the marker dye BCECF-AM.

10

Experimental conditions:

- 12-well micro-titer plates were filled with approximately 2ml of NGM agar (containing 1ml/l of ampicillin (100 μ g/ml) and 5 ml of 100mM stock 15 IPTG) per well
- the dried plates were spotted with 25 μ l of an overnight culture of bacteria (BL21DE3/HT115DE3) containing the plasmids pGN1 (T7prom-T7prom) or pGN8 (T7prom-unc-22-T7prom)
- 20 - individual nematodes at the L4 growth stage were then placed in single wells, one nematode per well
- the plates were incubated at 20°C for 6 days to allow offspring to be formed
- 25 - the adult F1 offspring of the seeded nematodes were tested for the twitching phenotype

Results:

Table 2:

	20°C/6d	pGN1 HT115DE3	pGN8 BL2DE3	pGN8 HT115DE3	
5	N2	0	1	1	
	<i>nuc-1</i>	0	1-2	3	
	<i>bg77</i>	0	1-2	3	
	<i>bg78</i>	0	1	1-2	
10	<i>bg83</i>	0	1	1	
	<i>bg84</i>	0	1-2	3	
	<i>bg85</i>	0	1	2-3	
	<i>bg86</i>	0	1	2	
	<i>bg87</i>	0	1	1	
15	<i>bg88</i>	0	1	1	
	<i>bg89</i>	0	1	1	

figure legend:

0 = no twitching

20 1 = no to weak phenotype

2 = clear phenotype

3 = strong phenotype

25 **Conclusions**

- bacterial strain HT115(DE3) shows a better RNAi sensitivity than bacterial strain BL21(DE3)
- the *nuc-1* *C. elegans* strain is a better strain than the Wild-type N2 strain for RNAi sensitivity
- 30 - various gun mutants (improved gut uptake mutants) and more particularly the gun mutant strains *bg77*, *bg84*, *bg85*, *bg86* show improved sensitivity to RNAi compared to Wild-type.

A double mutant *C. elegans* strain (nuc-1/gun) shows even greater sensitivity to RNAi compared to wild-type:

5 Double mutants were constructed to test the prediction that gun/nuc mutants would even show more enhanced RNAi sensitivity. As an example, the crossing strategy with gun strain bg85 is shown, similar crosses can be conducted with other gun strains, such
10 as bg77, bg84 and bg86.

P0 cross: gun(bg85) x WT males

F1 cross: nuc-1 x gun(bg85)/+ males

15 F2 cross: nuc-1 x gun(bg85)/+; nuc-1/0 males (50%)
nuc-1 x +/++; nuc-1/0 males (50%)

20 F3 single: gun(bg85)/+; nuc-1 hermaphrodites (25%)
+/++; nuc-1 hermaphrodites (75%)

F4 single: gun(bg85); nuc-1 (1/4 of every 4th
plate high staining with BCECF)

25 F5 retest: gun(bg85); nuc-1 (100% progeny of F4
singled high staining with BCECF)

30 To select for the gun phenotype, the fluorescence precursor BCECF-AM is used (obtainable from Molecular probes). The precursor BCECF-AM is cleaved by esterases present in the gut of the worm to generate the dye BCECF which is fluorescent at pH values above 6. This allows selection for worms that have a gun phenotype. BCECF-AM is taken up through the pharynx
35 into the gut lumen and is not fluorescent until it has been cleaved, and the BCECF portion has entered the

cells surrounding the lumen. Wild-type worms will show slower or no increase in BCECF fluorescence.

5 **Example 3**

Improved RNAi feeding in liquid culture using *nuc-1*(e1393) *C. elegans*.

Introduction

10 N2 and *nuc-1* *C.elegans* strains were fed with bacteria producing dsRNAs that give lethal phenotypes via RNAi. For this example RNAi was performed in liquid culture instead of on agar plates. We show here for a number of genes that the RNAi effect is more penetrant using 15 the *nuc-1* strain than the N2 strain, and that RNAi can be performed in liquid.

For this experiment the following *E.coli* strains were used:

20

1. HT115 (DE3): F- *mcrA mcrB* *IN(rrnD-rrnE)* 1 λ -*rnc14::tr10* (DE3 lysogen: lacUV5 promoter -T7 polymerase)
 - host, for IPTG inducible T7 polymerase expression
 - RNaseIII⁻
 - Fire A, Carnegie Institution, Baltimore, MD, Pers. Comm.

25 For this experiment, following *C. elegans* strains were used:

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans* *nuc-1*(e1393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death;

ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described: e1392 (strong allele: has been used for the experiments described below); n887 (resembles

5 e1392) and n334 (weaker allele)

- Stanfield et al. (1998) East Coast Worm meeting abstract 171
- Anonymous, Worm Breeder's Gazette 1(1):17b
- Hevelone et al. (1988) Biochem. Genet. 26:447-461
- 10 - Ellis et al., Worm breeder's Gazette 7(2):44
- Babu, Worm Breeder's gazette 1(2):10
- Driscoll, (1996) Brain Pathol. 6:411-425
- Ellis et al., (1991) Genetics 129:79-94

15

For this experiment, the following plasmids that all give lethal phenotypes in *C. elegans* via RNAi were used:

20

pGX22: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid C04H5.6 corresponding to a member of the RNA helicase family.

25

pGX52: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid K11D9.2b corresponding to sarco/endoplasmic Ca²⁺ ATPase also known as SERCA.

30

pGZ18: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid T25G3.2 corresponding to a chitin like synthase gene.

35

pGX104: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid Y57G11C.15 corresponding to sec-61, a transport protein.

Experimental conditions

- 1 ml overnight cultures of HT115 (DE3) bacteria containing the plasmids pGX22, pGX52, pGZ18 or pGX104 respectively were pelleted and resuspended in S-complete medium, containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 5
- 10 µl of this bacterial solution was transferred to a 96-well microtiter plate already filled with 100 µl S-complete containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 10
- 3 nematodes at the L1 growth stage of N2 and nuc-1 strain were then placed in single wells, 3 L1's per well. Per experimental set up, 16 wells were used (n=16).
- 15
- the plates were incubated at 25 °C for 5 days to allow offspring to be formed.
- 20
- the plates were visually checked and the following phenotypes could be scored per individual well:
- 25 **no effect:** L1's developed to adults and gave normal offspring.
- no F1 offspring: L1's developed to adults and gave no offspring.
- 30 **acute lethal:** original L1 did not mature and died.

Results

- 35 The results of this experiment are illustrated graphically in Figures 9 to 12. Data are expressed as

a percentage of the total (n=16) on the y-axis for both N2 and *nuc-1* strains.

Conclusions

5 The following genes were tested in this liquid RNAi assay:

- C04H5.6: an RNA helicase. RNAi of this gene interferes with the generation of offspring.
- 10 - SERCA: a sarco/endoplasmic Ca^{2+} ATPase. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- T25G3.2: a chitin like synthase gene. RNAi of this gene causes dead eggs.
- 15 - sec-61: a transport protein. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- 20 - RNAi can be performed under liquid conditions.

As in the previous examples this set of experiments shows that the *nuc-1* *C. elegans* strain is more sensitive to RNAi than the wild-type N2 strain. This is most clear for less penetrant phenotypes such as SERCA and chitin synthase. For strong RNAi phenotypes like the helicase and Sec-61 the difference between the N2 wild-type strain and the *nuc-1* stain is less pronounced.

Example 4**Cloning of pGX22, pGX52, pGZ18 and pGX104 for RNAi**

A set of primers for each gene was designed on the basis of sequence data available in the publicly

5 accessible *C. elegans* sequence database (Acedb).

The cosmid names relate to:

1. **C04H5.6**=member of RNA helicase
- 10 2. **K11D9.2b**=SERCA
3. **Y57G11C.15**=transport protein sec-61
4. **T25G3.2**=chitin synthase like

The following primer sequences were designed:

15

1. **C04H5.6F** 5'-TGCTCAGAGAGTTCTAACGAACC-3'
C04H5.6R 5'-CAATGTTAGTTGCTAGGACCACCTG-3'

20

2. **K11D9.2bF** 5'-CAGCCGATCTCCGTCTTGTG-3'
K11D9.2bR 5'-CCGAGGGCAAGACAACGAAG-3'

3. **Y57G11C.15F** 5'-ACCGTGGTACTCTTATGGAGCTCG-3'
Y57G11C.15R 5'-TGCAGTGGATTGGGTCTTCG-3'

25

4. **T25G3.2F**
5'-GGGGACAAGTTGTACAAAAAAGCAGGCTATGCCAAGTACATGTCGATTGCG-3'

T25G3.2R

5'-GGGGACCACCTTGTACAAGAAAGCTGGGTTGGAGAACGATTCCGAGAGTTG-3'

30

PCR was performed on genomic DNA of N2 strain *C. elegans* to give PCR products of the following sizes:

35 1326bp for C04H5.6
1213bp for K11D9.2b

1024bp for Y57G11C.15

1115bp for T25G3.2

5 The PCR fragments of C04H5.6, K11D9.2b and Y57G11C.15
were linked to *Bst*XI adaptors (Invitrogen) and then
cloned into the pGN29 vector cut with *Bst*XI. pGN29
contains two T7 promoters and two T7 terminators
flanking a cloning site which is adapted for
facilitated cloning of PCR fragments, comprising a
10 stuffer DNA flanked by two *Bst*XI sites (see schematic
Figure 3). The resulting plasmids were designated
pGX22 (C04H5.6), pGX52 (K11D9.2b) and pGX104
(Y57G11C.15).

15 The PCR fragment of T25G3.2 was cloned into pGN39 via
recombination sites based on the GATEWAY™ cloning
system (Life Technologies, Inc). pGN39 contains two
T7 promoters and two T7 terminators flanking a cloning
site which facilitates "High Throughput" cloning based
20 on homologous recombination rather than restriction
enzyme digestion and ligation. As shown schematically
in Figure 4, the cloning site comprises *att*R1 and
*att*R2 recombination sites from bacteriophage lambda
flanking a gene which is lethal to *E. coli*, in this
25 case the *ccdB* gene. This cloning site is derived from
the Gateway™ cloning system commercially available
from Life Technologies, Inc. The Gateway™ cloning
system has been extensively described by Hartley et
al. in WO 96/40724 (PCT/US96/10082).

Example 5

Selecting *C. elegans* mutations for increased gut uptake (gun) using marker dye BCECF-AM and *unc-31* as background.

5

The screen was performed in *unc-31*(e928) mutant background, to ensure high amounts of dye in the gut lumen, since *unc-31* mutations show constitutive pharyngeal pumping. The dye (BCECF-AM: 2',7' bis (2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester), obtained from Molecular Probes, is cleaved by intracellular esterases. Fluorescence accumulates in the gut cells upon passage through the apical gut membrane.

10

15

Mutagenesis

Day 1: *unc-31* L4 staged worms were mutagenised with EMS (final concentration 50 mM) for 4 hours

20 Day 2: P0 was divided over several large agar plates

Day 6: F1's were collected and dropped on large plates. The number of eggs the F1's layed were checked every hour and de F1's were removed when 10-20 eggs per F1 were counted

25 Day 10: F2 adults were collected and screened with BCECF-AM. Mutations with increased staining of the gut cells after 15-30 minutes exposure to the dye were selected and singled on small agar plates.

30

About 50 initial positives gave progeny which was retested with BCECF-AM (2x) and leucine CMB (1x) 9 of the 50 strains were kept (2 strains : 3 times positive, 7 other strains : twice positive)

35

Table 3: Isolation of mutations for increased staining with BCECF-AM

	Total P0	Total F1	Total F2	screened chromosomes	number of strains isolated
5	(counted)	(estimated)	(calculated)	(estimated)	(counted)
	2251	55618	222472	100000	9

Outcrossing, backcrossing and double construction

10 1. backcrossing *unc-31; gun* --> *unc-31; gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains segregating 1/4 unc
 15 - stain unc strains with BCECF-AM
 - from positive strains pick unc homozygous
 - retest 100 % unc strains with BCECF-AM
 - kept 1 strain (backcrossed)

20 2. *unc-31* background was crossed out-->+; *gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains which did not segregate unc F3s
 25 anymore
 - stain non unc strains with BCECF-AM
 - 7 positive strains were retested with BCECF-AM and finally 1 was selected and kept (outcrossed)

30 3. +; *gun* (1x outcrossed) were 2 times backcrossed-->+; *gun* (3x backcrossed)
 - *gun* x WT males
 - WT hermaphrodites x F1 males (*gun/+*)
 - singled 10 WT hermaphrodites F2s (1/2 heterozygous)
 35 - singled 50 WT hermaphrodites F3s (1/8 homozygous)

- 31 -

- stain strains with BCECF-AM- retested positives with BCECF-AM and finally 1 was selected and kept

4. *gun* (3x backcrossed) were crossed with *nuc-1*(X)

5 mutant--> *gun; nuc-1*

- *gun* x WT males
- *nuc-1* x *gun/+* males
- *nuc-1* x *gun/+; nuc-1/0* or *+/+; nuc-1/0* males
- singled 10 WT hermaphrodite progeny (*nuc-1* homozygous, $\frac{1}{2}$ heterozygous *gun*)
- singled 40 WT hermaphrodite progeny (1/8 homozygous *gun*)
- stain strains with BCECF-AM
- retested positives with BCECF-AM and finally 1 was selected and kept

Table 6: Strains derived from *gun* mutations

20	<i>gun</i>	<i>unc-31; gun</i>		<i>unc-31; gun</i>		<i>+/; gun</i>			<i>gun; nuc-1</i>
		original isolate		backcrossed (1x)		outcrossed (1x)		3x b.c.	from 3x b.c.
	allele number	isolation number	strain number	isolation number	strain number	isolation number	strain number	strain number	strain number
25	bg77	31.4	UG 510	31.4.46.1	UG 556	31.4.34	UG 563	UG 674	UG 777
	bg78	37.5	UG 511	37.5.46.4	UG 557	37.5.15	UG 564	UG 675	-
	bg83	10.2	UG 543	10.2.11	UG 600	10.2.21	UG 586	UG 676	-
	bg84	7.2	UG 544	7.2.10	UG 601	7.2.15	UG 589	UG 677	UG 774
	bg85	11.5	UG 545	11.5.29.2	UG 602	2x b.c.	UG 717		UG 775
30	bg86	42.1	UG 546	42.1.4.5	UG 603	42.1.18	UG 587	UG 678	UG 776
	bg87	7.1	UG 547	7.1.8.3	UG 604	7.1.22	UG 585	UG 679	-
	bg88	5.3	UG 548	5.3.9	UG 605	5.3.18	UG 584	UG 680	-
	bg89	23.4	UG 549	23.4.13.5	UG 606	23.4.3	UG 588	UG 671	-

SEQUENCE LISTING:

SEQ ID NO: 1 complete sequence of pGN1

5 SEQ ID NO: 2 complete sequence of pGN8

SEQ ID NO: 3 complete sequence of pGN29

10 SEQ ID NO: 4 complete sequence of pGN39

SEQ ID NO: 5 complete sequence of pGX22

15 SEQ ID NO: 6 complete sequence of pGX52

SEQ ID NO: 7 complete sequence of pGX104

20 SEQ ID NO: 8 complete sequence of pGZ8

SEQ ID NO: 9 primer C04H5.6F

SEQ ID NO: 10 primer C04H5.6R

25 SEQ ID NO: 11 primer K11D9.2bF

SEQ ID NO: 12 primer K11D9.2bR

SEQ ID NO: 13 primer Y57G11C.15F

30 SEQ ID NO: 14 primer Y57G11C.15R

SEQ ID NO: 15 primer T25G3.2F

SEQ ID NO: 16 primer T25G3.2R

Claims:

1. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to 5 said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode 10 has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.

2. A method as claimed in claim 1 wherein the 15 nematode is a microscopic nematode.

3. A method as claimed in claim 2 wherein the nematode is from the genus *Caenorhabditis*.

20 4. A method as claimed in claim 3 wherein the nematode is *C. elegans*.

25 5. A method as claimed in any one of claims 1 to 4 wherein the nematode has a mutant genetic background.

30 6. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits reduced activity of one or more nucleases compared to wild type.

7. A method as claimed in claim 6 wherein the nematode is *C. elegans* strain *nuc-1*.

35 8. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits increased

gut uptake compared to wild type.

9. A method as claimed in claim 8 wherein the nematode is mutant *C. elegans* strain bg85.

5

10. A method as claimed in claim 5 wherein the nematode is a mutant strain having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type.

10

11. A method as claimed in claim 10 wherein the nematode is a mutant *C. elegans* strain having the *nuc-1* mutation and the bg85 mutation.

15

12. A method as claimed in any one of the preceding claims wherein the food organism has been engineered to express a double-stranded RNA.

20

13. A method as claimed in any one of the preceding claims wherein the food organism is a bacterium.

25

14. A method as claimed in claim 13 wherein the food organism is *E. coli*.

30

15. A method as claimed in any one of the preceding claims wherein the food organism has been genetically modified to express a double-stranded RNA having a nucleotide sequence substantially identical to a portion of said target gene.

35

16. A method as claimed in claim 15 wherein the food organism contains a DNA vector, the vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of

initiating transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

5

17. A method as claimed in claim 25 wherein the vector comprises two promoters flanking the DNA sequence.

10

18. A method as claimed in claim 26 wherein the two promoters are identical.

15

19. A method as claimed in claim 25 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

20

20. A method as claimed in any one of claims 16 to 20 wherein the nematode or the food organism is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

25

21. A method as claimed in any one of claims 16 to 20 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

30

22. A method as claimed in any one of claims 1 to 21 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

35

23. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a

portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a modification selected to provide increased expression or persistence of the double-stranded RNA compared to a food organism which does 5 not carry the modification.

24. A method as claimed in claim 23 wherein the food organism is a bacterium.

10

25. A method as claimed in claim 24 wherein the bacterium is an *E. coli* strain.

15

26. A method as claimed in claim 25 wherein the *E. coli* strain is an RNase III minus strain or any other RNase negative strain.

20

27. A method as claimed in any one of claims 23 to 26 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

25

28. A method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

30

29. A method as claimed in claim 28 wherein the nematode is a microscopic nematode.

35

30. A method as claimed in claim 29 wherein the nematode is from the genus *Caenorhabditis*.

31. A method as claimed in claim 30 wherein the

nematode is *C. elegans*.

32. A method as claimed in any one of claims 28 to 31 wherein the nematode has a mutant genetic
5 background.

33. A method as claimed in claim 32 wherein the nematode is mutant *C. elegans* strain bg85.

10 34. A method as claimed in any one of claims 28 to 33 wherein the DNA capable of producing a double-stranded RNA structure is a vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of initiating
15 transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

20 35. A method as claimed in claim 34 wherein the vector comprises two promoters flanking the DNA sequence.

25 36. A method as claimed in claim 35 wherein the two promoters are identical.

30 37. A method as claimed in claim 34 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

35 38. A method as claimed in any one of claims 34 to 37 wherein the nematode is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

39. A method as claimed in any one of claims 34

to 38 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

FIG. 1




FIG. 2.




FIG. 3.




FIG. 4.




FIG. 5.




FIG. 6.




FIG. 7.




FIG. 8.




FIG. 9.




FIG. 10.




FIG. 11.





FIG. 12.



1
SEQUENCE LISTING

<110> DEVGEN NV

<120> IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

<130> SCB/53711/001

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.0

<210> 1

<211> 3216

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN1

<400> 1

gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcacatca 60
ggcggaaattt gtaaacgttaa tattttgtta aaattcgcgt taaaatattt ttaaatcagc 120
tcatttttta accaataggc cggaaatcgcc aaaaatccctt ataaatcaaa agaatagacc 180
gagatagggt tgagtgttgt tccaggttgg aacaagagtc cactattaaa gaacgtggac 240
tccaaacgtca aaggggcggaa aaccgtctat caggggcgatg gcccactacg tgaaccatca 300
cccaaatcaa gtttttgcgc gtcgaggtgc cgtaaagctc taaatcgaaa ccctaaagg 360
agcccccgat ttagagcttg acggggaaag cccggcgaacg tggcgagaaaa ggaagggaaag 420
aaagcggaaag gaggcgccgc tagggcgctg gcaagtgttag cggtcacgct ggcgttaacc 480
accacaccccg cccgcgttaa tgccggccta caggggcggt ccattcgcca ttcaggctgc 540
gcaactgttg ggaagggcga tcgggtcgccc cctcttcgct attacgcccag ctggcgaaag 600
ggggatgtgc tgcaaggcga ttaagttggg taacgcccagg gtttcccag tcacgacgtt 660
gtaaaaacgac ggcaggatgaa ttgttaatacg actcactata gggcgaattc gagctcggt 720
cccggggatc ctctagagtc gaaagcttct cgccctatag tgagtctgtat tacagcttga 780
gtattctata gtgtcaccta aatacggttgg cgtaatcatg gtcatagctg tttcctgtgt 840
gaaattgtta tccgctcaca attccacaca acatacgagc cggaaagcata aagtgtaaag 900
cctgggtgc ctaatgagtg agctaactca cattaatttc gttgcgtca ctggccgtt 960
tccagtcggg aaacctgtcg tgccagctgc attaatgaat cggccaaacgc gcggggagag 1020
gcgggttgcg tattggcgc tcttcgctt cctcgctcac tgactcgctg cgctcggtcg 1080
ttcggctgcg gcgagcggta tcagctcaact caaaggcggt aatacggtt tccacagaat 1140
cagggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta 1200
aaaaggccgc gttgctggcg ttttcgata gctccgc cccgtacgag catcacaaaa 1260
atcgacgctc aagttagagg tggcgaaacc cgacaggact ataaagatac caggcgttc 1320
cccctggaaag ctccctcggt cgctctcgtt tccgaccct gcccgttacc ggataacctgt 1380
ccgccttct ccctcgggaa agcgtggcgc tttctcatag ctcacgctgt aggtatctca 1440
gttcgggtga ggtcggttcgc tccaaagctgg gctgtgtgca cgaacccccc gttcagcccg 1500
accgctgcgc ctatccggta aactatcgtc ttgagtccaa cccgtaaaga cacgacttat 1560
cgccactggc agcagccact ggtaacagga tttagcagagc gaggtatgtt ggcgggtgcta 1620
cagagttttt gaaatgggtgg cctaaactacg gctacactag aaggacagta tttggtatct 1680
gcgcctcgct gaaaggccaggta accttcggaa aaagagttgg tagctcttga tccggcaaac 1740
aaaccaccgc tggttagcggt ggttttttgg tttgcaagca gcagattacg cgcagaaaa 1800
aaggatctca agaagatccct ttgatctttt ctacgggggtc tgacgcttag tggAACGAAA 1860
actcagctta agggattttg gtcatgagat tatcaaaaaag gatcttcacc tagatccctt 1920
taaattaaaa atgaagttttt aaatcaatct aaagtatata tgagtaact tggctgaca 1980

gttacccaatg	cttaatcagt	gaggcaccta	tctcagcgat	ctgtctattt	cgttcatcca	2040
tagttgcctg	actccccgtc	gtgttagataa	ctacgatacg	ggagggctta	ccatctggcc	2100
ccagtgtcgc	aatgataccg	cgagaccac	gctcaccggc	tccagattt	tcagcaataa	2160
accagccagc	cggaaaggcc	gagcgcagaa	gtggtcctgc	aactttatcc	gcctccatcc	2220
agtctattaa	ttgttgcgg	gaagctagag	taagtagttc	gccagttaat	agtttgcgca	2280
acgttgttgg	cattgtcaca	ggcatcgtgg	tgtcacgctc	gtcggttgg	atggcttcat	2340
tcagctccgg	ttcccaacga	tcaaggcgag	ttacatgatc	ccccatgtt	tgcaaaaaag	2400
cggtagctc	cttcggctc	ccgatcgttg	tcagaagtaa	gttggccgca	gtgttatcac	2460
tcatggttat	ggcagcactg	cataattctc	ttactgtcat	gccatccgta	agatgcttt	2520
ctgtgactgg	tgagtagtactca	accaagtcat	tctgagaata	ccgcgcccgg	cgaccgagtt	2580
gctcttgccc	ggcgtcaata	cgggataata	gtgtatgaca	tagcagaact	ttaaaagtgc	2640
tcatcattgg	aaaacgttct	tcggggcgaa	aactctcaag	gatcttaccg	ctgttggat	2700
ccagttcgat	gtAACCCact	cgtgcaccca	actgatcttc	agcatcttt	actttcacca	2760
gcgtttctgg	gtgagcaaaa	acaggaaggc	aaaatgccgc	aaaaaaaggga	ataagggcga	2820
cacggaaatg	ttgaataactc	atactttcc	tttttcaata	ttattgaagc	atttatcagg	2880
gttattgtct	catgagcgga	tacatattt	aatgtattta	aaaaaaataaa	caaataagggg	2940
ttccgcgcac	attccccga	aaagtgcac	ctgacgtcta	agaaaaccatt	attatcatga	3000
cattaaccta	taaaaatagg	cgtatcacga	gcccctttcg	tctcgcgcgt	ttcgggtatg	3060
acggtgaaaa	cctctgacac	atgcagctcc	cgagacggt	cacagcttgt	ctgtaaaggcg	3120
atgccgggag	cagacaagcc	cgtcaaggcg	cgtcagcggg	tgttggcggg	tgtcggggct	3180
qgcttaacta	tgcggcatca	gagcagattt	tactga			3216

<210> 2
<211> 4620
<212> DNA
<213> Arti

<220>
<223> Description of Artificial Sequence: Plasmid pGN8

<210> 3
<211> 4756

<212> DNA

<213> Art:

THEORETICAL APPROXIMATIONS

223

2220. Beschreibung der Ausstellung im Landesmuseum Berlin

<400> 3

tgctcagaga gtttctcaaa gaaccggatt tggctagtta taggttaattt tttagaacatt 60
tacaaaaaaca gcaaaaaaac caaacattca ggattttgt ttttaattaa gaaaaaaatc 120
gatcgctttt aaattttat caatacttcg aataaaccctt aaaaaaaacg aaaaaaaatc 180
ctgtttccag tgaatgatg attgacgagg ctcacgaacg tactctacac acggatattc 240
tattcgggtt agtcaaagat attgcaagat tccgaaagga tttgaagctt ctcatcttt 300
ctgcaacact tgacgctgaa aagttctcca gtttcttcgaa cgacgctccg attttccgaa 360
ttccgggacg cagattcccg gtggacattt actatacaca ggctcccgaa gcggactacg 420
tcgacgcggc tatcgtcaca attatgcaga ttcacttgac ccagccactt cccggcgata 480
ttttgggtt tctgactggt caggaagaaa tcgaaactgt acagaagca cttatggac 540
ggtcgaaagc actgggatcg aagattaagg agcttattcc gtcggcggtt tatgcaatt 600
tgcccagtga tttcaggcg aagatttcg agccaacgccc gaaagatgcg agaaaggtag 660
attttttta caaattttt caaaaaaaaa atccgagaaa aatctacaaa attcagcgca 720
aaaactgttt cattttattt ctaacttagt ttttagcaaa cgtagtattt taacaaaact 780
gaacaaattt gaagttttcc aattttaaaaa ataaatgttt cggaaagtttt atgaaaaat 840
ctgaaattgc tatcctctcg tatctgcaaa aaaaacactt taaaaatgc tctgttctt 900
gaaaatttct aactgaaaaa atttggaaatt tctggaaaattt gtgataattt tataaaat 960
tatagaaaaat gtaagcattt cagaaaaataa tcaaaaaattt cgagaaaaattt ctgaaaaat 1020
ccagaaatat taacagaaaa aaaaatttt gaaacatctg aaaaattttt taaatttgc taaattgaat 1080
ttacattttt ttttttgggaa ttccctttaaa atcactatga atttaccatc aaattttttt 1140
caaaaaattttaa ttttttttaat ttcaaaagaaa aagcaaaagaa tttttttaaa tcaaaaatgc 1200
caaattttggt tgggtgaattt tttaaaaataa cattttcaag ataaattttttaa gttaaatcaaa 1260
acattccacg catttcttagt ttcccaaattt tctctaaattt tcagtggtc ctagcaacta 1320
acattggccag cacaatggat ctcgaggat ttccatacc taccgttct ggcctctaa 1380
gtcgccggccg cgactctcta gacgcttaag cttacttaga taacccttg gggcctctaa 1440
acgggtcttg aggggttttt tgagcttctc gccctatagt gagtcgtt gacggtttag 1500
tattctatag tgcacccctaa atagcttggc gtaatcatgg tcatactgtgt tccctgtgt 1560
aaattttttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agttaaaggc 1620
ctggggtgcc taatgagtga gctaactcac attaatttgcg ttgcgtcact tggccgttt 1680
ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggcaacacgccc 1740
cggtttcggtt attgggcgtt cttccgttcc ctcgctcaact gactcgctgc gctcggtcg 1800
tcggctcggtt cgagcggat cagctcaactt aaaggcggta atacggttat ccacagaatc 1860
aggggataac gcagggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa 1920
aaaggcccgcg ttgctggcgt tttcgatag gctccgcccc cctgacgagc atcacaaaaa 1980
tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgttcc 2040
ccctggaaacg tccctcggtc gctctctgttccgaccctg ccgttaccg gatacgttc 2100
cgcccttctc ctttcgggaa gctggcgtt ttctctatgc tcacgctgtt ggtatcttag 2160
ttcgggttag gtcgttccgtt ccaagctggg ctgtgtgcac gaaccccccgg ttcagccgaa 2220
ccgctgcgtt ttatccggta actatcgct ttagtccaac ccgttaagac acgacttac 2280
gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgttag gccgtgtcac 2340
agagttctt gaaatggggc gtaactacgg ctacactaga aggacagtat ttggtatctg 2400
cgctctgtt gaaatccgtt cttccggaaa aagagttgtt agctcttgcg cccggcaaaaca 2460
aaccaccgtt ggtagcgggtt gttttttgtt ttgcaagcag cagattacgc gcaaaaaaaa 2520
aggatctcaa gaagatccctt tgatcttttacgggggtt gacgctcgtt ggaacgaaaa 2580
ctcacgtttaa gggattttgg tcatgagatt atcaaaaaagg atcttcaccc agatcctttt 2640
aaattttttttaa tgaatgtttt aatcaatcta aagtatatat ggttaaactt ggtctgacag 2700
ttaccaatgc ttaatcgtt aggcacccat ctcagcgatc tgcgttattt gttcatccat 2760
agttgcgttga ctccccgtcg ttagataac tacgataacgg gagggcttac catctggccc 2820
cagtgctgca atgataccgc gagaccacg ctcacccgctt ccagattttt cagcaataaa 2880
ccagccagcc ggaaggcccg agcgcagaag tggcctcgca actttatccg cctccatcca 2940
gtctattaaat tggccgggg aagcttaggt aagtagttcg ccagttataa gtttgcgcaa 3000
cggttgcgtt attgctacag gcatcgttgcgtt gtcacgctcg tggcttggta tggcttcat 3060
cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgcgtt gcaaaaaaagc 3120
ggttagctcc ttcggctctc cgatcgttgcgtt cagaagtaag ttggccgcag tttttttttt 3180
catggttatg gcagcactgc ataatttctt tactgtcatg ccattccgtaa gatgcttttc 3240
tgtgactggt gactactcaa ccaagtcattt ctgagaataac cgcggccggc gaccgagttt 3300
ctttggcccg gctgtcaatac gggataatag tttatgacat agcagaactt taaaagtgtt 3360

catcatttga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tggtgagatc 3420
 cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatcttta ctttcaccag 3480
 cgttctggg tgagcaaaaa caggaaggca aaatgccgc aaaaaggaa taagggcgac 3540
 acggaaatgt tgaatactca tactcttcct tttcaatat tattgaagca tttatcaggg 3600
 ttattgtctc atgagcggat acatattga atgtatttag aaaaataaac aaatagggt 3660
 tccgcgcaca tttccccaa aagtgcacc tgacgtctaa gaaaccatta ttatcatgac 3720
 attaacctat aaaaataggc gtatcacgag gcccittcg ctcgcgcgt tcggtgatga 3780
 cggtaaaaac ctctgacaca tgcagctccc ggagacggtc acagcttgc tctaagcgaa 3840
 tgccgggagc agacaagccc gtcagggcgc gtcaggggt gttgggggt gtcgggctg 3900
 gcttaactat gccgcacatcag agcagattgt actgagagtg caccatatgc ggtgtaaat 3960
 accgcacaga tgcgttaagga gaaaataccg catcaggcg aattttaaac gttaatattt 4020
 tgttaaaatt cgcgttaaat atttggtaaa tcaagtcatt ttttaaccaa taggcccggaa 4080
 tcggcaaaat cccttataaa tcaaaaagaat agaccgagat agggttgagt gttgttccag 4140
 tttggaaacaa gagtccacta ttaaagaacg tggactccaa cgtcaaaggcg cggaaaaccg 4200
 tctatcaggg ccatggccca ctacgtgaac catcacccaa atcaagttt ttgcggtcg 4260
 ggtgccgtaa agctctaaat cggAACCTA aaggggagccc ccgattttaga gcttgacggg 4320
 gaaagccggc gaaacgtggcg agaaaggaaag ggaaggaaagc gaaaggagcgc ggcgctagg 4380
 cgctggcaag ttagtgcgtc acgctgcgcg taaccaccac acccgccgcg cttaatgcgc 4440
 cgctacaggg cgcgtccatt cgcattcag gctgcgcac tggactggaaag ggcgatcggt 4500
 gcgggcctct tcgctattac gccagctggc gaaagggggg tggctgcgaa ggcgattaaag 4560
 ttgggttaacg ccagggtttt cccagtcacg acgttgtaaa acgacggccca gtgaatttga 4620
 atacgactca ctataggcg aattcaaaaa acccctcaag acccggttag aggcccccaag 4680
 gggttatgct agtgaattct gcagggttacc cggggatcct ctagagatcc ctcgacctcg 4740
 agatccatttgc tgcttg 4756

<210> 4
 <211> 4643

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX52

<400> 4

 gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcattca 60
 ggcgaaatttgc taaacgttaa tattttgtta aatttcgcgt taaatatttgc ttttttttttgc 120
 tcatttttta accaataggc cggaaatcgcc aaaaatccctt ataaatcaaa agaatagacc 180
 gagatagggt ttagtgcgt tccagggtgg aacaagagtc cactattaaa gaacgtggac 240
 tccaacgtca aaggggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
 cccaaatcaaa gttttttgcg gtcgagggtgc cgtaaagctc taaatcgaa ccctaaagg 360
 agcccccgat ttagagcttgc acggggaaag cccgcgaacg tggcgagaaa ggaagggaag 420
 aaagcgaaag ggcgggcgc tagggcgctg gcaagtgttag cggtcacgct ggcgtaacc 480
 accacaccccg cccgcgtttaa tgcgcgcgtc cagggcgctg ccattcgcca ttcaaggctgc 540
 gcaactgttgc ggaaggggcgaa tgggtgcggg cctttcgctt attacgcccag ctggcgaaag 600
 ggggatgtgc tgcaggcgaa ttaagggtgg taacgcccagg gttttcccgat tcacgacgtt 660
 gtaaaacgcac ggcagggtgaa ttgtataacg actcaactata gggcgaattt aaaaacccc 720
 tcaagaccccg tttagaggcc ccaagggtttt atgctgtgttgc atttgcagg gtacccgggg 780
 atcctctaga gatccctcgat cctcgagatc cattgtgcgt gcagccgtat tccgtctgt 840
 gaagatctac tccaccacca tccgtatcga tcagtcacatc ctcaccggag aatctgtgc 900
 tggttatcaag cacaccgact ctgtgcgcaga tccacgcgt gtttaccagg acaagaagaa 960
 ttgtctgttc tggggaaacca atgtgcgcac tggaaaggct cgtgaatcg tcttcggaaac 1020
 cggattgacc actgaaatcg gaaagatccg taccgaaatcg gctgagaccg agaatgagaa 1080
 gacaccactt caacagaagt tggacgaaatt cggagagccaa ctttccaaagg ttatctctgt 1140
 tatttgcgtt gctgtttggg ctatcaacat tggacatttc aacgatcccg ctcacgggtgg 1200
 atcatgggtt aaggggagcaa tctactactt caaaatcgcc gttgtcttg ccgtcgctgc 1260
 tattccagaa ggacttcccg ctgtcatcaccac tggatccctt gcccctcgaa ctcgcccgtat 1320
 ggccaaagaag aacgcttatttgc taagatccct tccatccgtc gaaacttgc gatgcacatc 1380
 tggttatctgc tctgacaaga ctggaaactctt caccaccaac cagatgtctg tggatccatc 1440

gttcatcgct ggacaagctt ctggagacaa catcaacttc accgagttcg ccatctccgg 1500
 atccacctac gagccagtcg gaaaggttc caccaatgga cgtaaaatca acccagctgc 1560
 tggagaattc gaatcaactca ccgagttggc catgatctgc gctatgtca atgattcatc 1620
 tggattac aatgagacca agaagatcta cgagaaagtgc ggagaagcca ctgaaaactgc 1680
 tcttacgtt cttgctgaga agatgaatgt tttcggaacc tcgaaagccg gacttcacc 1740
 aaaggagctc ggaggagttt gcaaccgtgt catccaacaa aaatggaaga aggagttcac 1800
 actcgatcc tcccgtgatc gtaaaatccat gtccgcctac tgcttcccag ctccggagg 1860
 atctggagcc aagatgttcg tgaagggagc cccagaagga gttctcgaa gatgcaccca 1920
 cgtcagagtt aacggacaaa aggttccact cacctctgcc atgactcaga agattgttga 1980
 ccaatgcgtg caatacggaa ccggaagaga tacccttcgt tgcgttgc 2040
 caatggatct cgagggtatct tccataccta ccagttctgc gcctgcagg cgccgcgcg 2100
 actctctaga cgcgtaaatc tactagcata accccttggg gcctctaaac gggctttag 2160
 gggtttttg agcttctcgcc cctatagtga gtcgttattac agctttagta ttctatagt 2220
 tcacctaataat agcttggcgt aatcatggc atagctgtt cctgtgtgaa attgttatcc 2280
 gctcacaatt ccacacaaca tacgagccgg aagcataaaag tgtaaagcct ggggtgccta 2340
 atgagtgagc taactcacat taattcggtt ggcgttactg cccgtttcc agtcgggaaa 2400
 cctgtcgcc cagctgcatt aatgaatcg ccaacgcgcg gggagaggcg gtttgcgtat 2460
 tggcgctct tccgcttcct cgctcaactga ctcgctgcgc tcggcggtt ggctgcggcg 2520
 agcggatca gctcaactcaa aggccgtaat acggttatcc acagaatcag gggataaacgc 2580
 aggaaagaac atgtgagc aaggccagca aaaggccagg aaccctaaaa aggccgcgtt 2640
 gctggcgctt ttcgataggc tccggccccc tgacgagcat cacaaaaatc gacgctcaag 2700
 tcagagggtgg cggaaacccga caggactata aagataaccag gcgttccccctt ctggaaagctc 2760
 cctcggtcgc tctcctgttc cgaccctgcg gcttaccggc tacctgtccg ccttctccc 2820
 ttcggaaagc gtggcgctt ctcatacgctc acgctgttagg tatctcagtt cgggttaggt 2880
 cggtcgctcc aagctgggct gtgtgcacga acccccccgtt cagccgacc gctgcgcctt 2940
 atccggtaac ttcgtcttgc agtcaaccc ggtaaagacac gacttatcgc cactggcagc 3000
 agccactggt aacaggatta gcagagcggat gtatgttaggc ggtgtacag agttcttggaa 3060
 gtggtggcct aactacggct acactagaag gacagtattt ggtatctcgc ctctgctgaa 3120
 gccagttacc ttccggaaaaa gagttggtag ctcttgcattt ggcacaaaa ccaccgcgtt 3180
 tagcggtgg tttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 3240
 agatcccttg atctttctca cgggtctga cgctcagtttgg aacggaaaact cacgttaagg 3300
 gattttggtc atgagattat caaaaaggat cttcaccttag atccctttaa attaaaaatg 3360
 aagttttaaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt accaatgtt 3420
 aatcagttag gacccatctc cagcgatctg tctatttcgt tcatccatag ttgcctgact 3480
 ccccgctgtg tagataacta cgatacggga gggcttacca tctggcccca gtgctgcaat 3540
 gataccgcga gacccacgcg caccgcgtcc agatttatca gcaataaacc agccagccgg 3600
 aagggccgag cgccagaatgt gtcctgcac ttatccggc tccatccagt ctattaattt 3660
 ttggccggaa gctagagtaa gtagttcgcc agttaatagt ttgcgcacg ttgttggcat 3720
 tgctacaggc atcgtgggtt cacgctcgcc gtttggtagt gtttgcattca gctccgggtt 3780
 ccaacgatca aggcgagttt catgatcccc catgttgc aaaaaagccgg ttagctcctt 3840
 cggtcctccg atcgttgtca gaagtaagtt ggcgcagtg ttatcactca tggttatggc 3900
 agcactgcat aattctctta ctgtcatgcc atccgtaaaga tgctttctg tgactgggtga 3960
 gtactcaacc aagtcttgc gagaataccg cggccggcga ccgagttgtctt cttggccggc 4020
 gtcaataacgg gataatagtg tatgacatag cagaacttta aaagtgcac tcattggaaa 4080
 acgttcttcg gggcgaaaaac tctcaaggat cttaccgcgtt ttgagatcca gttcgatgt 4140
 acccactcgt gcacccaaact gatcttcgcg atctttact ttccaccagcg ttctgggtt 4200
 agcaaaaaaca ggaaggcaaa atgcccggaaa aaagggaata agggcgacac ggaaatgtt 4260
 aataactcata ctttccctt ttcaatattt ttgaagcatt tatcagggtt attgtctcat 4320
 gagcggatac atatttgaat gtatttagaa aaataaacaa ataggggttc cgccgcacatt 4380
 tccccggaaaaa gtggccacccgt acgtctaaga aaccattatt atcatgacat taacctataa 4440
 aaataggcgt atcaccggc ctttcgttcc cgccgcgttcc ggtgtatgcgt gtggaaacct 4500
 ctgacacatcg cagctcccg agacggtcac agcttgcgtt taagcggatg ccgggagcag 4560
 acaagccccgt cagggcgcgt cagcgggtgt tggcggtgtt cggggctggc ttaactatgc 4620
 ggcacatcgag cagattgtac tga 4643

<210> 5

<211> 4454

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX104

<400> 5

gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcacca 60
ggcggaaattt taaacgttaa tattttgtta aaattcgcgt taaatatttgc ttaaatcagc 120
tcattttttta accaataggc cggaaatcgcc aaaatccctt ataaatcaaa agaatagacc 180
gagatagggt tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
tccaaacgtca aaggggcggaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
cccaaatcaa gtttttgcg gtcgaggtgc cgtaaagctc taaatcgaa ccctaaaggg 360
agccccccat tttagagcttgc acggggaaag ccggcgaacg tggcgagaaa ggaagggaaag 420
aaagcggaaag gagcgggcgc tagggcgctg gcaagtgttag cggtcacgct ggcgtaaacc 480
accacaccccg ccgcgtttaa tgcgcgccta cagggcgctg ccattcgcca ttcaggctgc 540
gcaactgttg ggaagggcga tcgggtcgccc cctttcgtt attacgcccag ctggcgaaag 600
ggggatgtgc tgcaaggcga ttaagttggg taacgcccagg gttttccag tcacgacgtt 660
gtaaaacgcac ggcagtgaa ttgttaatcgc actcactata gggcgaattt aaaaaacccc 720
tcaagaccccg ttagaggcc ccaagggggtt atgcttagtgc attctgcagg gtacccgggg 780
atcctctaga gatccctcgat cctcgagatc cattgtcgctg gaccgtggta ctcttatgg 840
gctcggaaatc tcgccaatcgc tcacttctgg acttataatcgc caacattctcg ccggagccaa 900
gatcatcgaa gtcggagacac caccaaaagga ccgtgcctt ttcaacggag cccagaaatg 960
taagccgaaa agtgtgtgtt ttcaatctct aatttttgcgaa cttttcgttgc ttccgtatgg 1020
tcatcactgt tgacaagatcgtt atgtctacgc tcatgtccgg actctacggc gagccatcg 1080
aaatcggagc tggaaatctgtt ctccttatcgc tcgtccaaact cgttatttgc ggtctcatcg 1140
tcctcccttcg ctagcggactt ctccaaaagg gatatggctt cggatccggat atttctct 1200
tcattgcccac caacatctgtt gaaaccatttgc tctggaaaggc attctcccg gcaacaatga 1260
acaccggacg tggaaaccggat ttcgaaggag ccgtcatttgc tctttccat ctctttgc 1320
cccgctccgat ctaggtccgtt gcccctcgat aggttttgc ttcgtccaaact ctccaaact 1380
tgatgaactt gatggctact ttccctcgat ttgcgggtgtt tatctacttc caaggatcc 1440
gtgtcgaccc cccaatcaag tctgcggctt accgtggaca atacagcgc taccatca 1500
agctctctca cacctccaaatcatttcaatc tccctcaatc tgctctcgat tccaaacct 1560
acgttatctc tcaggtttgtt tgcatctcgtt tagtaccgtt agatgtttat ctttctct 1620
agggtaactt tgcccgagaa attttttgcgat ttcattctca agtctgtatgg aaaaatgttta 1680
tttttcgtt gctcgccggat aagttcgat gaaacttctt catcaacatc tccgttaccc 1740
ggtccgataa caccggatatac agaagctacc caactggagg actctgttac tatctttcac 1800
caccagatc tcttggacac atcttgcgaa acccaatcca ctgcaccaggc acaatggatc 1860
tcgagggttcc ttccatcacctt accaggctcgat cgcctgcagg tcgccccgc gactctct 1920
acgcgttaatc ttacttagcat aacccttgcgat ggcctctaa cgggtcttgc ggggtttttt 1980
gagcttctcg ccctatagttt agtctgttcaatc cagtttgcgtt attctatagt gtcacccat 2040
tagcttggcg taatcatgtgtt catagctgtt ttctgtgtgcgaaatttttgc ttcgtccaaat 2100
tccacacaac atacgagccg gaaagatcaaa gtgtaaaggcc tgggggtgcctt aatgagtgag 2160
ctaactcaca ttaattgcgt tgcgttactt gcccgccttc cagtcggggaa acctgtcgat 2220
ccagctgcata taatgaatcgc gccaacgcgc ggggagaggc gtttgcgtt ttgggcgtc 2280
ttccgcgttcc tcgcttacttgcg actcgcgttgcgat ctcgttgcgtt cggctgcggc gaggcggtatc 2340
agctcaactca aaggcggttacatc ttcgttacttgcgat cacagaatca ggggataacg caggaaagaa 2400
catgtgagca aaggccggatc aaaaaggccatc gaaaccgttacatc aaggccgcgt tgctggcgat 2460
tttcgtatagg ctccggccccc ctgacggatca tcacaaaaat ctagctcaatc gtcagagggt 2520
gcaaaaccccg acaggactat aaagataccat ggcgtttccc cctggaaatc ccctcgatc 2580
ctctccgtt ccgcggccctgc cgcttaccggat acatctgtcc gccttctcc ttcggggaaag 2640
cggtggcgat ttcgttacttgcgat ctcgttgcgtt gtttgcgtt ccgttgcgtc 2700
caagctggc ttttttttttgcgat aaccggccgtt ctagccgcac cgtgcgcctt ttttttttttgc 2760
ctatcgatcc ttttttttttgcgat ctcgttgcgtt ccgttgcgtt ttttttttttgc 2820
taacaggattt acgcggccgtt acgttttttttgcgat ctcgttgcgtt ttttttttttgc 2880
taactacggc tacactagaa ggacagtattt ttttttttttgcgat ctcgttgcgtt ttttttttttgc 2940
cttcggaaaa agatcttgcgtt gtcgttgcgtt ccgttgcgtt ttttttttttgc 3000
tttttttttttgcgat ctcgttgcgtt ccgttgcgtt ttttttttttgc 3060
gatctttctc acgggggtctgc acgttgcgtt ccgttgcgtt ttttttttttgc 3120

catgagatta	tcaaaaagga	tcttcaccta	gatcctttta	aattaaaaat	gaagttttaa	3180
atcaatctaa	agtatatatg	agtaaacttg	gtctgacagt	taccaatgct	taatcagtga	3240
ggcacctatc	tcagcgatct	gtctatttcg	ttcatccata	gttgcctgac	tccccgtcg	3300
gtagataact	acgatacggg	agggcttacc	atctggcccc	agtgctgaa	tgataccgcg	3360
agacccacgc	tcaccggctc	cagatttata	agcaataaac	cagccagccg	gaagggccga	3420
gcgcagaagt	ggtcctgcaa	ctttatccgc	ctccatccag	tctattaatt	gttgcggga	3480
agctagagta	agtagttcgc	cagttaatag	tttgcgcaac	gttgttggca	ttgctacagg	3540
catcgtggtg	tcacgctcg	cgtttgtat	ggcttcattc	agctccggtt	cccaacgatc	3600
aaggcgagtt	acatgatccc	ccatgttgc	caaaaaagcg	gttagctct	tcggtcctcc	3660
gatcgttgtc	agaagtaagt	tggccgcagt	gttacactc	atggttatgg	cagcactgca	3720
taattctctt	actgtcatgc	catccgtaag	atgctttct	gtgactggtg	agtactcaac	3780
caagtcatc	tgagaataacc	gcccggcg	accgagttgc	tcttgcggg	cgtcaatacg	3840
ggataatagt	gtatgacata	gcagaacttt	aaaagtgc	atcattggaa	aacgttcttc	3900
ggggcggaaa	ctctcaagga	tcttaccgct	gtttagatcc	agttcgatgt	aaccactcg	3960
tgcacccaac	tgatcttcag	catctttac	tttcaccagc	gtttctgggt	gagaaaaaac	4020
aggaaggcaa	aatgcccga	aaaaggaaat	aagggcgaca	cggaaatgtt	gaataactcat	4080
actcttcctt	tttcaatatt	attgaagcat	ttatcaggt	tattgtctca	tgagcggata	4140
catatttcaa	tgtattttaga	aaaataaaca	aataggggtt	ccgcccacat	ttccccgaaa	4200
agtgcacca	gacgtctaag	aaaccattat	tatcatgaca	ttaacctata	aaaataggcg	4260
tatcacgagg	ccctttcgtc	tcgcgcgtt	cggtgatgac	ggtaaaaacc	tctgacacat	4320
gcagctcccg	gagacggtca	cagcttgtct	gtaagcggat	gccgggagca	gacaagcccg	4380
tcagggcgcg	tcagcgggtg	ttggcgggtg	tcggggctgg	cttaactatg	cgccatcaga	4440
gcagattgt	ctga					4454

<210> 6
<211> 4701
<212> DNA
<213> Arti

<220>
<223> Description of Artificial Sequence: Plasmid pGZ18

<400> 6	acccagcttt	cttgtacaaa	gtggtgatct	ttccagcaca	atggatctcg	aggatcttc	60
catacctacc	agttctgcgc	ctgcaggctcg	cgccgcgcac	tctctagacg	cgtaagctta	120	
ctagcataac	cccttggggc	ctctaaacgg	gtcttgaggg	gttttttag	cttctcgccc	180	
tatagtgagt	cgttattacag	tttgagttt	ctatagtgtc	acctaaatag	tttggcgtaa	240	
tcatggtcat	agctgtttcc	tgtgtaaaat	tgttatccgc	tcacaattcc	acacaacata	300	
cgagccggaa	gcataaaagt	taaaggctgg	ggtgcctaatt	gagttagct	actcacat	360	
attgcgttgc	gctcaactgc	cgttccag	tcgggaaacc	tgtcggtcca	gctgcattaa	420	
tgaatcgccc	aacgcgcggg	gagaggcggt	ttgcgtattt	ggcgcttcc	cgcttcctcg	480	
ctcaactgact	cgtcgctc	ggtcgttccg	ctgcggcgag	cggtatcagc	tcactcaaag	540	
gccccataac	ggttatccac	agaatcaggg	gataacgcag	gaaaacat	gtgagcaaaa	600	
ggccagcaaa	aggccaggaa	ccgtaaaaag	gcccgcgttgc	tggcgtttt	cgttaggctc	660	
cgcggccctg	acgagcatca	caaaaatcga	cgctcaagtc	agaggtggcg	aaacccgaca	720	
ggactataaa	gataccaggc	gtttccccct	ggaagctccc	tcgtcgctc	tcctgttccg	780	
accctggcgc	ttaccggata	cctgtccggc	tttctccctt	cggaaagcgt	ggcgcttct	840	
catagctcac	gctgttaggt	tctcagttcg	gtgttaggtcg	ttcgctccaa	gctgggctgt	900	
gtgcacaaac	cccccggtca	gcccgaccgc	tgccgccttat	ccggtaacta	tcgtcttgc	960	
tccaaaccgg	taagacacga	ttatcgcca	ctggcagcag	ccactggtaa	caggattagc	1020	
agagcgaggt	atgttaggcgg	tgctacagag	ttcttgaagt	ggtggcctaa	ctacggctac	1080	
actagaagga	cagtatttgg	tatctgcgt	ctgctgaagc	cagtacatt	cggaaaaaga	1140	
gttggtagct	cttgatccgg	caaacaacc	accgctggta	gccccgggtt	ttttgttgc	1200	
aagcagcaga	ttacgcgcag	aaaaaaagg	tctcaagaag	atcccttgc	cttttctacg	1260	
gggtctgacg	ctcagtgaa	cgaaaaactca	cgttaaggga	ttttggtcat	gagattatca	1320	
aaaaggatct	tcaccttagat	ccttttaat	taaaaatgaa	gttttaaattc	aatctaaagt	1380	
atatatgagt	aaacttggtc	tgacagttac	caatgcttaa	tcagtggc	acctatctca	1440	
gcatctgtc	tatccgttcc	atccatagtt	gcctgactcc	ccgtcggtta	gataactacg	1500	

atacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga cccacgctca 1560
 ccggctccag atttatcgc aataaaccag ccagccggaa gggccgagcg cagaagtgg 1620
 cctgcaactt tatccgcctc catccagtct attaattgtt gccggaaagc tagagtaatg 1680
 agttcccgag ttaatagttt ggcacacgtt gttggcattt ctacaggcat cgtgggtca 1740
 cgctcgctgt ttggatggc ttcattcagc tccgggtcccc aacgatcaag gcgagttaca 1800
 tgatccccca tgggtgcaaa aaaagcggtt agtccctcg gtcctccgat cgttgtcaga 1860
 agtaagtgg ccgcagtgtt atcaactcatg gttatggcag cactgcataa ttctcttact 1920
 gtcatgccat ccgtaaagatg ctttctgtg actgggtgagt actcaaccaa gtcattctga 1980
 gaataccgcg cccggcgcacc gagttgtct tgccggcgt caatacgggta taatagtgt 2040
 tgacatagca gaactttaaa agtgctcatc attggaaaac gttctcggg gcgaaaactc 2100
 tcaaggatct taccgcgtt gagatccagt tcgatgtaac ccactcggtc acccaactga 2160
 tcttcagcat ctttacttt caccagcggt tctgggtgag caaaaacagg aaggcaaaaat 2220
 gccgcaaaaaa agggataaaag ggcgacacgg aaatgttcaa tactcataact cttccctttt 2280
 caatattattt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt 2340
 atttagaaaaa ataaaacaaat aggggttccg cgcacatttc cccgaaaagt gccacctgac 2400
 gtctaagaaa ccattattat catgacattt acctataaaa ataggcgtat cacgaggccc 2460
 tttcgctctcg cgctttcg tcatgtacggt gaaaacctct gacacatgca gctccggag 2520
 acggtcacag ctgtctgtt agcggatgcc gggagcagac aagccgtca gggcgcgtca 2580
 gcccgggtttg gcccgggtcg gggctggctt aactatgcgg catcagagca gattgtactg 2640
 agagtgcacc atatgcgtt taaaataccg cacagatgcg taaggagaaa ataccgcattc 2700
 aggcgaaattt gtaaacgttta atattttgtt aaaattcggg ttaaatattt gttaaatcatg 2760
 ctcattttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac 2820
 cgagataggg ttgagtggtt ttccagtttgaacaagagt ccactattaa agaacgtgga 2880
 ctccaaacgtc aaaggcgcga aaaccgtcta tcagggcgat ggcggactac gtgaaccatc 2940
 acccaaatca agtttttgc ggtcgagggtt cctgttttttgcgat ctaaatcgga accctaaagg 3000
 gagccccgaa tttagagctt gacggggaaa gcccggcgaac gtggcgagaa aggaaggaa 3060
 gaaagcgaaa ggagcggggcg cttagggcgct gcgaagtgta gcccggcgtc tgcgcgtac 3120
 caccacaccc gccgcgttta atgcggcgctt acagggcgat tccattcgcc attcaggctg 3180
 cgcaactgtt gggaaaggcg atcgggtcg ggcctttcg tattacgcca gctggcgaaa 3240
 gggggatgtg ctgcaaggcg attaagttgg gtaacgcggat ggttttccca gtcacgcgt 3300
 tgtaaaacga cggccagtgtt attgtataatc gactcaactat agggcgaaattt caaaaaaccc 3360
 ctcaagaccc gtttagaggc cccaaagggtt tatgtctgtt aatttgcgtt ggtacccggg 3420
 gatcctctag agatccctcg acctcgagat cattgtgtt ggaagcgtt tgcagggtcg 3480
 gcaagccacg ttgggtgggt ggcacatcc tccaaaatca acaagttgtt acaaaaaaagc 3540
 aggctatgcc aagtacatgt cgattgcgtt cgcgttgcgtt atgtggctg tgtagtcgc 3600
 taccagcgtt caaattgttc tcgagatgtc gtttttacat tatccctca tcctgattac 3660
 gacaattttc agctgttctc gctccatcat ctctttcat tgcacatgtt gtcggaaatct 3720
 tcttcttgc tgcattgttcat catccaaaatc aattcactgaa tattatccat ggtgtcgat 3780
 tcttcctcat gattccatct acatatgtgt tcctcactt atattcgctc atcaatctca 3840
 acgttatcac gtggggaaact cgtgaagctg tcgctaaaggc aacgggacaa aagacgaaaa 3900
 aagcgcttat ggaacaattt atagacagag tgattgtat tgcggaaaatg ggattcagat 3960
 taatcgttgc tcgggagaag aaggaaacatg aagagagacg agagaaaatg gaaaagaaaa 4020
 tgcagagaat ggagctagcc ttgagaagta ttgagggtt cttaactttt agaaatgtga 4080
 aattaataat ttattttcgtt agtgggtccg acgtgaagaa aatttctcgat gcaacagagg 4140
 agaaggagaa acgtgaagaa gaaactcaaa ctgcagat tccgattgaa gagaacgttag 4200
 agaagactca aaaagagattt cagaaggcgg accgttatgt gtggatgaca agtcataatgt 4260
 tggaaagggtt tgaacgcgggaa aactgaaaaa gtgcggaaaaa gttttctgg aacgagctca 4320
 tcaatgcata tctgaaaccg atcaagacga cggccagctga aatgaaagcc gtcggccaaag 4380
 gattggcttc tctacgaaat cagattgtt tcactatttct tctcgat tctcttcttgc 4440
 ctcttgcatttcttgcattt cagaacaca aaaaatgtgtt cagcatcaag ttctcgccaa 4500
 tcagtaagca atattacattt tatggtcaat tcaaaaaattt tggtttttttt ttctagaaaa 4560
 cttccgatgg acgaaaatgtt atgagatgac tggacaatc gaggaaaccg atgaaccattc 4620
 aaaaatagat ccacttggaa tggaaattgt tggtttccctt ctaattatttcc tttttgttca 4680
 aactctcgatccatc atgcttctcc a 4701

<210> 7

<211> 25

<212> DNA

10

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide primer C04H5.6F

<400> 7

tgctcagaga gtttctcaac gaacc

25

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer C04H5.6R

<400> 8

caatgttagt tgctaggacc acctg

25

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bF

<400> 9

cagccgatct ccgtcttgtg

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bR

<400> 10

ccgagggcaa gacaacgaag

20

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15F

<400> 11

accgtggtagt tcttatggag ctcg

24

<210> 12

11

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide
primer Y57G11C.15R

<400> 12
tgcaagtggat tgggtcttcg

20

<210> 13
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide
primer T25G3.2F

<400> 13
ggggacaagt ttgtacaaaa aaggcaggcta tgccaaagtac atgtcgattg cg

52

<210> 14
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide
primer T25G3.2R

<400> 14
ggggaccact ttgtacaaga aagctgggtt ggagaagcat tccgagagtt tg

52

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48183 A3

(51) International Patent Classification⁷: C12N 15/10. (74) Agent: BAYLISS, Geoffrey, Cyril; Boult Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(21) International Application Number: PCT/EP00/13149

(81) Designated States (national): AE, AG, AL, AM, AT, AU,

(22) International Filing Date:
22 December 2000 (22.12.2000)

AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:

— with international search report

(30) Priority Data:
9930691.2 24 December 1999 (24.12.1999) GB

(88) Date of publication of the international search report:
6 December 2001

(71) Applicant (for all designated States except US): DEV-GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): PLAETINCK, Geert [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE). MORTIER, Katherine [BE/BE]; Paddenhoek 20, B-9830 St.-Martens Latem (BE). LISSENS, Ann [BE/BE]; Tiens-esteenweg 137, B-3010 Kessel-Lo (BE). BOGAERT, Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).

WO 01/48183 A3

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/13149

A. CLASSIFICATION OF SUBJECT MATTER	IPC 7 C12N15/10 C12N9/22 C07K14/435 C12N15/66 C12N15/70
	C12N1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TIMMONS L ET AL: "Specific interference by ingested dsRNA" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 395, no. 6705, 29 October 1998 (1998-10-29), page 854 XP002103601 ISSN: 0028-0836 the whole document</p> <p>---</p> <p>FIRE A ET AL: "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i>" NATURE, MACMILLAN JOURNALS LTD. LONDON, vol. 391, 19 February 1998 (1998-02-19), pages 806-811, XP002095876 ISSN: 0028-0836 cited in the application the whole document</p> <p>---</p> <p>---</p>	1-4, 12-21, 23-25, 28-31, 34-39
A		1-4
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

5 July 2001

Date of mailing of the international search report

20/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL 2280 HV Rijswijk
 Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/13149

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHARP PHILLIP A: "RNAi and double-strand RNA." GENES & DEVELOPMENT, vol. 13, no. 2, 15 January 1999 (1999-01-15), pages 139-141, XP002171268 ISSN: 0890-9369 the whole document ---	1-4
A	RAY C ET AL: "GUT-SPECIFIC AND DEVELOPMENTAL EXPRESSION OF A CAENORHABDITIS ELEGANS CYSTEINE PROTEASE GENE" MOLECULAR AND BIOCHEMICAL PARASITOLOGY, NL, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 51, 1992, pages 239-249, XP000572340 ISSN: 0166-6851 abstract ---	2-4, 8
A	RAND J B ET AL: "GENETIC PHARMACOLOGY: INTERACTIONS BETWEEN DRUGS AND GENE PRODUCTS IN CAENORHABDITIS ELEGANS" METHODS IN CELL BIOLOGY, LONDON, GB, vol. 84, 1995, pages 187-204, XP000956211 page 190, paragraph 1 -page 194, paragraph 4 ---	1-4, 8
A	AVERY LEON ET AL: "The Caenorhabditis elegans unc-31 gene affects multiple nervous system-controlled functions." GENETICS, vol. 134, no. 2, 1993, pages 455-464, XP001011453 ISSN: 0016-6731 the whole document ---	2-4, 8
A	TAGESSON C ET AL: "INFLUENCE OF SURFACE-ACTIVE FOOD ADDITIVES ON THE INTEGRITY AND PERMEABILITY OF RAT INTESTINAL MUCOSA" FOOD AND CHEMICAL TOXICOLOGY, vol. 22, no. 11, 1984, pages 861-864, XP001009621 ISSN: 0278-6915 the whole document ---	8 -/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/13149

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	LYON CHRISTOPHER J ET AL: "The <i>C. elegans</i> apoptotic nuclease NUC-1 is related in sequence and activity to mammalian DNase II." GENE (AMSTERDAM), vol. 252, no. 1-2, 11 July 2000 (2000-07-11), pages 147-154, XP001009494 ISSN: 0378-1119 abstract; figure 3 page 151, right-hand column, paragraph 2 -page 153, right-hand column, paragraph 2 ----	6,7
P,X	WO 00 01846 A (MORTIER KATHERINE ;DEVGEN NV (BE); BOGAERT THIERRY (BE); PLAETINCK) 13 January 2000 (2000-01-13) cited in the application page 8, line 9 -page 10, line 22 page 12, line 14 -page 23, line 2 figures 5,9; examples 1-4 ----	1-4, 12-21, 23-25, 28-31, 34-39
P,X	WO 00 63425 A (FEICHTINGER RICHARD ;BEGHYN MYRIAM (BE); DEVGEN NV (BE); BOGAERT T) 26 October 2000 (2000-10-26) abstract page 2, line 14-30 page 6, line 18-33 page 7, line 12 -page 9, line 28 page 12, line 20 -page 13, line 25; example 3 ----	2-5,8,9, 29-33
T	TIMMONS LISA ET AL: "Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in <i>Caenorhabditis elegans</i> ." GENE (AMSTERDAM), vol. 263, no. 1-2, 2001, pages 103-112, XP001009512 ISSN: 0378-1119 the whole document ----	1-4, 12-21, 23-26, 28-31, 34-39

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/13149

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 0001846	A 13-01-2000	AU 4907999 A	24-01-2000	EP 1093526 A	25-04-2001
		GB 2349885 A	15-11-2000	NO 20010019 A	05-03-2001
WO 0063425	A 26-10-2000	AU 3984600 A	02-11-2000	GB 2351152 A	20-12-2000